Friday, April 25, 2008

Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

April 25, 2008 - Urigen Pharmaceuticals, Inc. (OTCBB: URGP), http://www.urigen.comannounced that the U.S. Patent and Trademark Office issued a notice of allowance for claims for the first patent application for URG101, an investigational, bladder instillation for the treatment of Painful Bladder Syndrome/Interstitial Cystitis (PBS). These claims broadly cover URG101 and its use in the treatment of PBS by administering a glycosaminoglycan (such as heparin) and a local anesthetic.

Urigen recently closed a Phase II study of URG101 due to positive, statistically significant results at interim analysis with 50 percent patient enrollment. The Phase II study was a multi-center, double-blind, placebo-controlled, crossover designed clinical trial of URG101 in patients with PBS.

No comments: